title: Radiofrequency ablation of atrial fibrillation in patients with mechanical mitral valve prostheses safety, feasibility, electrophysiologic findings, and outcomes.
abstract: OBJECTIVE
  The purpose of this study was to evaluate the feasibility, safety, and outcomes of radiofrequency ablation of atrial fibrillation (AF) in patients with mechanical mitral valve replacement (MVR).
  
  
  BACKGROUND
  The role of ablative therapy in patients with MVR is not yet established, with safety concerns and very few outcome data.
  
  
  METHODS
  Between January 2003 and December 2008, we followed up 81 patients with MVR undergoing first-time AF ablation (compared with 162 age- and sex-matched controls). Arrhythmia recurrences were identified by symptoms with documentation, event monitoring, Holter monitoring, and electrocardiograms.
  
  
  RESULTS
  All MVR and control patients underwent ablation under therapeutic international normalized ratio. No entrapment of catheters or stroke occurred. There were no differences in terms of procedure-related complications between the groups (p = NS). Patients with MVR had larger atria (p < 0.0001), lower left ventricular ejection fractions (p = 0.0001), and more concomitant atrial flutter at baseline (p < 0.0001). Over a 24-month follow-up, they had higher recurrence rates compared with controls (49.4% vs. 27.7% after a single ablation, p = 0.0006). The creation of flutter lines significantly reduced recurrences in patients with any history of atrial flutter (16.7% vs. 60.9%, p = 0.009). At last follow-up, 82.7% of MVR patients had their arrhythmia controlled (69.1% not receiving antiarrhythmic drugs).
  
  
  CONCLUSIONS
  Radiofrequency ablation is feasible and safe for patients with MVR. It allowed restoration of sinus rhythm in a substantial proportion of patients undergoing ablation. An abnormal atrial substrate underlies recurrences in these patients. The ablation procedure needs to be further refined with a focus on extra pulmonary vein triggers and concomitant flutters to improve outcomes.
authors.affiliation: Center for Atrial Fibrillation, Cleveland Clinic, Cleveland, Ohio, USA.
authors.forename: Ayman A
authors.initials: AA
authors.lastname: Hussein
authors.forename: Oussama M
authors.initials: OM
authors.lastname: Wazni
authors.forename: Serge
authors.initials: S
authors.lastname: Harb
authors.forename: Lee
authors.initials: L
authors.lastname: Joseph
authors.forename: Mohammed
authors.initials: M
authors.lastname: Chamsi-Pasha
authors.forename: Mandeep
authors.initials: M
authors.lastname: Bhargava
authors.forename: David O
authors.initials: DO
authors.lastname: Martin
authors.forename: Thomas
authors.initials: T
authors.lastname: Dresing
authors.forename: Thomas
authors.initials: T
authors.lastname: Callahan
authors.forename: Mohamed
authors.initials: M
authors.lastname: Kanj
authors.forename: Andrea
authors.initials: A
authors.lastname: Natale
authors.forename: Bruce D
authors.initials: BD
authors.lastname: Lindsay
authors.forename: Walid I
authors.initials: WI
authors.lastname: Saliba
mesh_terms: D000368:Aged; D001281:Atrial Fibrillation / Q000532:radiotherapy*; D016022:Case-Control Studies; D017115:Catheter Ablation / Q000379:methods*; D004594:Electrophysiology / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D006350:Heart Valve Prosthesis; D006801:Humans; D008297:Male; D008875:Middle Aged; D008943:Mitral Valve / Q000473:pathology*; D008945:Mitral Valve Prolapse / Q000532:radiotherapy; D011846:Radio Waves; D012008:Recurrence; D016896:Treatment Outcome